Cardiovascular outcomes in patients over 75 years of age taking a statin for primary prevention by Taylor, S. R. et al.
Campbell University 
CU FIND 
Pharmaceutical Sciences Pharmacy & Health Sciences, College of 
2019 
Cardiovascular outcomes in patients over 75 years of age taking a 
statin for primary prevention 
S. R. Taylor 
D. Maybin 
A. J. Al-Achi 
Follow this and additional works at: https://cufind.campbell.edu/pharmacy 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Journal of Pharmacy Practice and Pharmaceutical Sciences [ISSN: 2652-2536]                                                   Submit Manuscript 
 .01.
                                                                                                                                                                                                         
OCIMUM
Research Article
Cardiovascular Outcomes in Patients Over 75 Years 
of Age Taking a Statin for Primary Prevention
Shawn Riser Taylor1*, Dustin Maybin2 and Antoine 
Al-Achi3
1Staff Pharmacist, Charles George VAMC, USA
2PGY1 Pharmacy Resident, Charles George 
VAMC, USA
3College of Pharmacy & Health Sciences, 
Campbell University, North Carolina, USA
Received: 18 April, 2019
Accepted: 05 June, 2019
Version of Record Online: 21 June, 2019
Citation
Taylor SR, Maybin D, Al-Achi A (2019) 
Cardiovascular Outcomes in Patients Over 
75 Years of Age Taking a Statin for Primary 
Prevention. J Pharm Pract Pharm Sci 2019(1): 
54-59.
Correspondence should be addressed to
Shawn Riser Taylor, USA
E-mail: s.taylor@wingate.edu
Copyright
Copyright © 2019 Taylor SR et al. This is an open 
access article distributed under the Creative 
Commons Attribution License which permits 
unrestricted use, distribution, and reproduction 
in any medium, provided the original author and 
work is properly cited.
Abstract
Background: The elderly population is rapidly growing, and there is limited 
evidence for the use of statins for primary prevention of Atherosclerotic 
Cardiovascular Disease (ASCVD) in this population.
Objective: The primary outcome of this study was a composite of the patient’s 
first cardiovascular event, defined as cardiovascular death, non-fatal Myocardial 
Infarction (MI) or non-fatal stroke (Three Point Major Adverse Cardiovascular 
Events: 3P-MACE).
Methods: This retrospective study examined the effect of statin therapy for 
primary prevention of cardiovascular outcomes in patients at least 75 years of 
age on moderate to high-intensity statin therapy.
Results: A total of 1853 patients were included in this study. Patients were more 
likely to experience the composite endpoint if they were in the statin group 
compared to the control group (19.7% versus 13.2%, p=0.0004). Patients in 
the statin group were significantly more likely to have a non-fatal MI or stroke 
compared to the control group (3.2% versus 0.5%, p<0.0001 and 14.1% versus 
10.4%, p=0.0193). Patients with diabetes were less likely to die from any cause 
if they received statin therapy when compared to the control group (19.18% vs. 
43.58%, p<0.0001).
Conclusion: In conclusion, statin therapy appears to be beneficial in elderly 
patients with diabetes. However, the same therapy was found to have no benefits 
against the primary composite endpoint in this population of patients.
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Background
Globally and nationally, Cardiovascular Disease (CVD) is the number one 
cause of death. Nearly 801,000 deaths in America-or 1 out of 3 deaths-each 
year can be attributed to CVD [1]. In 2015, approximately 17.7 million 
people died from CVD, accounting for 31% of all global deaths [2]. This 
is despite constant efforts to combat Major Adverse Cardiovascular Events 
(MACE) over the past several decades. Though partially due to modifiable 
risk factors, such as smoking, physical inactivity, poor diet, and obesity, age 
is also a robust predictor of CVD. In 2013, approximately 80% of deaths 
due to coronary heart disease in the United States occurred in people age
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65 years and older [3]. The relationship between CVD risk 
and age is of concern, especially considering the anticipated 
growth in the elderly population. Projections illustrate that 
the population of people over 65 years old in the United 
States is expected to increase from 13.7% to 20.3% between 
2012 and 2030. More specifically, those over the age of 75 
years are expected to nearly double in percentage in that 
same timeframe, going from 19.1 million people in 2012 to 
34.2 million people in 2030 [4]. As the elderly population 
grows, diagnoses of CVD and cardiovascular-related deaths are 
projected to increase. The medications collectively known as 
“statins” (3-Hydroxy-3-Methyl-Glutaryl Coenzyme A (HMG-
CoA) reductase inhibitors) are commonly recommendedfor 
the treatment of dyslipidemia and the prevention of CVD. 
Many studies have been done with this class of medications, 
demonstrating the efficacy of statins for primary and secondary 
prevention of Atherosclerotic Cardiovascular Disease (ASCVD) 
[5]. However, in most of these studies, the elderly population 
was frequently excluded, thus yielding a lack of basis for how 
to properly treat elderly patients. Trials that did include, and 
sometimes focus on, the elderly population and the use of 
statins, such as the PROSPER and SAGE trials, often only 
evaluated their use for secondary prevention of ASCVD [6,7]. 
Fortunately, these trials both showed that statins do reduce 
cardiovascular risk in elderly individuals with a history of prior 
ASCVD. However, whether this benefit exists for the primary 
prevention of ASCVD in elderly individuals without prior 
ASCVD could not be extrapolated from these studies. Other 
trials, such as CARDS and JUPITER, examined the use of 
statins for primary prevention of ASCVD in elderly patients 
and demonstrated a significant reduction in the incidence 
of Myocardial Infarction (MI), Coronary Heart Disease 
(CHD) death, revascularization, and unstable angina [8,9]. 
Unfortunately, these trials typically evaluated patients with 
mean ages between 65 and 75 years and rarely evaluated statin 
use for primary prevention in patients over the age of 75 years 
[7,8]. The age threshold of 75 years is particularly important 
when interpreting the various dyslipidemia guidelines that have 
published and adopted throughout the world. The most recent 
guideline published for the management of dyslipidemia in the 
United States, a collaboration between the American College of 
Cardiology (ACC) and the American Heart Association (AHA) 
in 2018, recommends moderate-intensity statin therapy for 
patients over the age of 75 years with ASCVD [10]. However, 
for those over 75 years old without prior ASCVD and a 10-
year CVD risk greater than 7.5%, no recommendations are 
provided. The 2017 guidelines published by the American 
Association of Clinical Endocrinologists (AACE) and the 
American College of Endocrinology (ACE), recommends 
that individuals over 75 years old with ASCVD risk factors 
be screened for dyslipidemia and treated to goal LDL-C and 
non-HDL-C [11]. The 2014 US Department of Veteran 
Affairs/Department of Defense (VA/DOD) guidelines do 
not provide specific guidance for the elderly population only 
noting that all patients with greater than 6% risk for CVD 
in the next ten years receive a moderate-intensity statin [12]. 
Due to the rapidly growing elderly population in the United 
States and abroad, as well as the limited evidence for the use of 
statins for primary prevention of ASCVD in elderly patients, 
it is apparent that more research is warranted in this area. 
In this study, we have evaluated the impact of moderate to 
high-intensity statin therapy for primary CVD prevention in 
patients over 75 years of age.
Methods
This retrospective study was conducted in a Veterans Affairs 
Medical Center. The study complied with the Declaration of 
Helsinki and the International Conference on Harmonization/
Good Clinical Practice Guidelines and was approved by the 
on-site VAMC Institutional Review Board (IRB).
The study examined the effect of statin therapy for primary 
prevention of cardiovascular outcomes in patients at least 
75 years of age on moderate to high-intensity statin therapy 
compared to a control group (Table 1). The primary outcome 
of this study was a composite of the patient’s first cardiovascular 
event, defined as cardiovascular death, non-fatal MI or non-fatal 
stroke (3P-MACE). Secondary endpoints included evaluation 
of each of the composite endpoints individually, as well as, 
all-cause mortality.
High Moderate Low
Atorvastatin 40mg-80mg Atorvastatin 10mg -20mg
Rosuvastatin 20mg-40mg Rosuvastatin 5mg-10mg
Simvastatin 10mg -40mg Simvastatin 10mg
Pravastatin 40mg -80mg Pravastatin 10mg-20mg
Lovastatin 40mg -80mg Lovastatin 20mg
Fluvastatin 80mg Fluvastatin 20mg-40mg
Table 1: Statin Intensity Daily Dose.
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Inclusion criteria included: age of at least 75 years and a 
prescription for moderate to high-intensity statin therapy for 
three or more consecutive years during the five-year study 
period (2012-2017) for the treatment group while those in 
the control group did not have an active prescription for a 
moderate or high-intensity therapy during the study period. 
Also, all patients had to have diagnosis of at least one ASCVD 
risk factor in addition to age, such as hypertension, diabetes 
mellitus, dyslipidemia, or current smoking status. Patients were 
excluded from the study if they had a diagnosis of unstable 
angina or prior ASCVD, as defined by the ACC/AHA, at the 
beginning of the study period [10].
A five-year study period was chosen to allow adequate time to 
analyze the rate of cardiovascular outcomes in each group given 
trials evaluating the cardiovascular benefit of statin therapy 
illustrated cardiovascular outcomes in similar follow-up time.
In order to provide a statistical power of 80% to detect a 
35% difference (a small effect size of 0.27) in the 3P-MACE 
occurrence between statin-treated patients and patients not 
receiving statin therapy with a two-sided significance level 
and an alpha of 0.05, 226 cardiovascular events were necessary 
(nQuery Advisor, Statistical Solutions Ltd, Boston, MA).
Patients were further sub-grouped based on their status of 
diabetes (Control = 296 with diabetes and 998 without diabetes; 
statin = 219 with diabetes and 340 without diabetes). A 
nominal logistic regression analysis was appliedto the data with 
Group (i.e., treatment vs. control) and Diabetes Status being 
the regressors. The model also contained an interaction term 
between the two regressors. A p-value < 0.05 was considered 
significant. The data were further analyzed using a Chi-
square test to examine the difference (in the % of patients 
experiencing the end-point) in the end-points between the two 
groups concerning patients with diabetes only. JMP Statistical 
Characteristic Control Group (1294) Statin Group (559)
Age mean (SD) 80.81 (4.04) 79.42 (3.55) †
Male gender n (%) 1265 (97.8) 546 (97.7)
Caucasian race (n) (%) 1230 (95.1) 543 (97.1)
Diagnosis of dyslipidemia n (%) 507 (39.2) 401 (71.7) †
Diagnosis of hypertension n (%) 1112 (86) 476 (85.1)
Diagnosis of diabetes n (%) 296 (22.9) 219 (39.2) †
Diagnosis of current smoking n (%) 136 (10.5) 46 (8.1)
BMI mean (SD) 25.64 (4.75) 26.82 (4.49) †
Table 2: Baseline Characteristics of Statin and Control Groups.
†Statistically significant difference between control and statin group
BMI: Body Mass Index; n: Number; SD: Standard Deviation
Discovery Software (SAS Institute, Cary, NC) was used for 
the statistical analysis.
Results
A total of 1853 patients were included in this study; this 
included every eligible patient identified in the electronic health 
record. Patients were either on moderate or high-intensity statin 
therapy (n=559) or not receiving a moderate or high-intensity 
statin (n=1294). Baseline characteristics are noted in table 2. 
There were fewer patients with diabetes in the control group 
compared to the statin group (p<0.0001). About 39% of the 
patients in the control group had a diagnosis of dyslipidemia, 
while approximately 72% of those in the statin group had 
dyslipidemia diagnoses (p<0.0001). The patients in the 
statin group had a higher Body Mass Index (BMI) (25.6 vs. 
26.8) (p<0.0001). Moreover, age was statistically greater in the 
control group (80.8 vs. 79.4 years) (p<0.0001).
Patients were more likely to experience the composite endpoint 
(CV death, non-fatal stroke or non-fatal MI) if they were in 
the statin group compared to the control group (19.7% versus 
13.2%, p=0.0004) as illustrated in table 3. Further, patients 
in the statin group were significantly more likely to have a 
non-fatal MI or stroke compared to the control group (3.2% 
versus 0.5% p<0.0001 and 14.1% versus 10.4% p=0.0193), 
respectively. All-cause mortality in the control group was 
observed at a rate more than double of that in the statin group 
(35.6% vs. 17.5%, p<0.0001).
The sub-group analysis detailed in table 4 revealed patients 
diagnosed with diabetes had a higher all-cause mortality 
compared to patients without diabetes regardless of the 
treatment. However, there was a higher percentage of patients 
with diabetes experiencing death in the control group versus 
patients without diabetes in the same group (43.58% vs. 
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33.27%, p=0.0011). This difference between patients with and 
without diagnoses of diabetes with respect to death was not 





Composite CV death, non-fatal stroke, non-fatal MI n (%) 171 (13.2) 110 (19.7) 0.0004
CV death n (%) 43 (3.4) 23 (4.1) 0.3988
Non-fatal MI n (%) 7 (0.5) 18 (3.2) <0.0001
Non-fatal stroke n (%) 134 (10.4) 79 (14.1) 0.0193
All-cause mortality n (%) 461 (35.6) 98 (17.5) <0.0001
Table 3: ASCVD Outcomes and All-Cause Mortality.
ASCVD: Atherosclerotic Cardiovascular Disease; CV: Cardiovascular; MI: Myocardial Infarction; n: Number
Composite CV death, non-fatal stroke, non-fatal MI (%)







0.1655 0.1222 0.21 0.1882
CV death (%)







0.0473 0.0291 0.0502 0.0353
Non-fatal MI (%)







0.0101 0.004 0.0365 0.0294
Non-fatal stroke (%)







0.125 0.0972 0.1507 0.1353
All-Cause Mortality in Sub-Group Analysis







0.4358 0.3327 0.1918 0.1647
Table 4: ASCVD Outcomes and All-Cause Mortality in Sub-Group Analysis.
DM: Diabetes Mellitus
aControl versus statins overall, regardless of diabetes diagnosis
bDiabetes versus non-diabetes overall, regardless of control or statin
Further, the data analysis found that statin therapy was beneficial 
in preventing death in patients with diabetes. Patients with 
diabetes were less likely to diefrom any cause if they received 
statin therapy when compared to the control group (19.18% 
vs. 43.58%, p<0.0001), however, a slightly higher percentage 
of patients experienced MI in the statin group as opposed to 
that in the control group (3.65% vs. 1.01%, p=0.0405). Statin 
therapy was not protective concerning the primary composite 
endpoint (p=0.0839).
Discussion
The benefits of statin therapy in middle-aged patients at risk 
for cardiovascular disease or with a history of cardiovascular 
disease is well-established. However, utilizing statins for 
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primary prevention in elderly patients remains a topic of 
debate. This study showed that in older patients, specifically at 
least 75 years of age there is potentially an all-cause mortality 
benefit for patients taking moderate or high intensity statins 
for at least three years. However, in the absence of diabetes, 
moderate to high-intensity statin therapy may not be beneficial 
in reducing the first occurrence of cardiovascular disease or 
death. In patients diagnosed with diabetes, statin therapy 
remained a beneficial pharmacological therapy in preventing 
all cause-mortality, however, did not provide a significant 
reduction in the primary outcome. Given the higher risk of 
mortality in diabetes, the benefits of statin therapy as it relates 
to mortality may be worth exploring further. In the absence 
of diabetes and a history of the established cardiovascular 
disease, however, this study remains to offer up any benefit for 
pharmacological intervention as a means to prevent CV death, 
non-fatal MI or non-fatal stroke. Potential limitations of the 
study include its retrospective nature and subsequent reliance on 
appropriate electronic health record coding. There were noted 
statistically significant differences in baseline characteristics. 
However, not all are presumed to be clinically significant 
(i.e., an age difference of 1.4 years and BMI difference of 
1.2kg/m2). It was not surprising to see significantly more 
patients diagnosed with diabetes and dyslipidemia on statin 
therapy as that follows recommendations from numerous 
clinical practice guidelines owing to higher atherosclerotic 
risks related to the pathophysiology of those diseases. Finally, 
patients in the control group could have been taking a low 
intensity statin or a moderate or high intensity statin with less 
than 80% adherence.
Safety was not evaluated in this trial but is another important 
aspect of future studies, specifically prospective designed trials, 
and warrants thorough discussion with patients falling in this 
age group at risk of cardiovascular disease.
The recently published guidelines by ACC/AHA for the 
management of dyslipidemia provide some insight into statin 
use in the elderly; however, only a few of the cited articles 
specifically address the population of 65 years and older [10]. 
A sub-analysis in ALLHAT-LTT of patients at least 75 years of 
age revealed no significant difference in coronary heart disease 
events, stroke or all-cause mortality between patients prescribed 
pravastatin 40mg daily versus usual care [13]. In contrast, a 
meta-analysis of the JUPITER and HOPE-3 trials showed that 
in patients at least 70 years of age taking rosuvastatin 10 or 
20mg the composite endpoint of non-fatal MI, non-fatal stroke 
and cardiovascular death was significantly reduced compared 
to placebo [14]. Age limitations are not explicitly stated in the 
VA DoD Clinical Practice Guidelines that note, “for primary 
prevention, we recommend a moderate dose statin as the agent 
of choice” with strong strength of recommendation. Evidenced 
by this trial and others, the favoring for or against statin therapy 
in elderly patients is not answered simply and requires a more 
in-depth analysis of reason to trial and potential risks.
In conclusion, statin therapy appears to be beneficial in elderly 
patients with diabetes. However, the same therapy was found 
to have no benefits against the primary composite endpoint 
in this population of patients (i.e., primary CVD prevention 
in patients over 75 years of age).
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